Navigation Links
S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Date:2/21/2012

JERSEY CITY, N.J., Feb. 21, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys).  Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD). 

Lorexys' clinical development plan is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA).  Lorexys is a novel use fixed-dose combination (FDC) in an oral enteric formulation acting on the central nervous system (CNS) with therapeutic characteristics that benefit sufferers of sexual health disorders.  It is intended as a treatment for HSDD both as a standalone and as an adjunct to testosterone therapy for the disorder.

"The IND filing for Lorexys is an important milestone for our Company," stated Nicolas G. Sitchon, Chief Executive Officer. "The Lorexys Clinical Development Program represents S1's entry into the significant Women's Sexual Health Disorders field with a lead drug candidate having several potential advantages over other treatment options in development."

On the condition of FDA endorsement of an approvable Investigational New Drug application for Lorexys, the Company will conduct Multiple Ascending Dose (MAD) safety, tolerability, and exploratory efficacy Phase I-b studies on Lorexys in 2012.  Upon successful completion, the results from these studies will satisfy FDA requirements to commence Phase II studies for HSDD patients.

About S1 Pharmaceuticals, Inc.

S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health.  The most common type of Female Sexual Dysfunction (FSD) is a distressing loss of libido (lack of sexual interest) known as Hypoactive Sexual Desire Disorder (HSDD).
'/>"/>

SOURCE S1 Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
2. Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals
3. Endo Pharmaceuticals to Present at J.P. Morgan Annual Global High Yield & Leveraged Finance Conference
4. Access Pharmaceuticals MuGard Added to Nationally Ranked Childrens Hospital of Colorado Pharmacy Formulary
5. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
6. Omthera Pharmaceuticals, Inc. to Present at Leerink Swann 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
7. Jazz Pharmaceuticals to Announce 2011 Full Year and Fourth Quarter Financial Results on February 27, 2012
8. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
9. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
10. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
11. Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014  Relmada ... therapies for the treatment of chronic pain, announced today ... Sloan Kettering Cancer Center (MSKCC) in a series of ... ER, a new tamper-resistant, extended release form of levorphanol. ... investigator for these studies. Dr. Pasternak ...
(Date:9/15/2014)... NEW YORK , Sept. 16, 2014 ... Neuropathy Foundation (HNF) announced today an agreement to collaborate ... disease and support the development of a stronger CMT ... provide financial support to several HNF,s initiatives including: ... section in the HNF website featuring  HNF newsletters, materials ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
Breaking Medicine Technology:Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 2FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 3FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 4FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 5FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 6FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 7FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 8FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 9FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 10FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 11Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 2Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 3Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 4Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 5Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 6
(Date:9/16/2014)... 16, 2014 Non-small cell lung cancer (NSCLC) survivors ... at the time of diagnosis have a lower ... compared to those who are current smokers, suggesting ... higher risk of SPLC, according to research presented ... (ASTRO,s) 56th Annual Meeting. , The analysis studied ...
(Date:9/16/2014)... 16, 2014 An experimental positron emission ... disease while a person is still alive, according to ... Medicine at Mount Sinai, and at Molecular Neuroimaging (MNI) ... the journal Translational Psychiatry. , Specifically, the study results ... which is designed to latch onto a protein called ...
(Date:9/16/2014)... VA (PRWEB) September 16, 2014 Gary ... Republic of China, has selected Worldwide Speakers Group for ... former U.S. Secretary of Commerce and Governor of Washington, ... foremost authorities on U.S.-China relations, global expansion, and business ... on global competitiveness and how to grow an organization’s ...
(Date:9/16/2014)... September 16, 2014 The Muscular ... of flu vaccines for individuals affected by muscle ... and other neuromuscular diseases. , MDA offers this ... muscle disease who, because of compromised respiratory function ... the lungs — are at increased risk of ...
(Date:9/16/2014)... Insuranceservicecompany.com has released a new blog post explaining ... , Whole life insurance can provide financial security for ... an investment tool. Clients can save money for retirement using ... A whole life insurance plan features a savings account which ... this policy to be profitable, clients should purchase it as ...
Breaking Medicine News(10 mins):Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2
... The Midwest Center for Stress and Anxiety announced ... the premier online destination for news, information and solutions ... new site features an enhanced user interface with access ... most pressing and relevant stress-related issues, and the newest ...
... Arizona Technology Enterprises (AzTE), the technology venturing arm ... technology forum for investors on Feb. 12 and 13, ... in Scottsdale, AzTE collaborated with its tech transfer partner, ... The forum was sponsored and supported by Silicon ...
... FRANCISCO, Feb. 18 DIAKADI Body, Personal ... its outdoor boot camps, the hottest and most economical workout ... a.m., individuals of all fitness levels will gather in Mission ... Stairs) to take their workout to the next level. ...
... Verathon(R) is pleased to announce,the GlideScope(R) Ranger Video ... States Army.(1) This certificate allows the,device to be ... of the most,demanding military settings. , ... The U.S. Army Airworthiness ...
... Achieves 20% Sales Growth over Q3 FY 08 and Record Quarterly ... ) today announced results for the quarter ended January 23, 2009. ... of fiscal 2009 compared to the third quarter of fiscal 2008 ... Net sales of $35.3 million, a 20% increase ...
... proves faster, more accurate in early tests , , WEDNESDAY, ... make prescribing the widely used anticoagulant warfarin safer by ... , The U.S. Food and Drug Administration estimates that ... blood clots that can cause strokes. Reasons range from ...
Cached Medicine News:Health News:The Midwest Center for Stress and Anxiety Re-launches Website for Stress, Anxiety, and Depression 2Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 2Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 3Health News:Arizona Technology Enterprises (AzTE) Hosts the ASU Tech Forum for the Investment Community 4Health News:Back by Popular Demand! DIAKADI Body Announces Its Spring Edition of Outdoor Boot Camps 2Health News:Back by Popular Demand! DIAKADI Body Announces Its Spring Edition of Outdoor Boot Camps 3Health News:GlideScope(R) Ranger Video Laryngoscope by Verathon(R) Awarded Airworthiness Certification by U.S. Army 2Health News:GlideScope(R) Ranger Video Laryngoscope by Verathon(R) Awarded Airworthiness Certification by U.S. Army 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 2Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 3Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 4Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 5Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 6Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 7Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 8Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 9Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 10Health News:Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter 11Health News:Genetics May Help Fine-Tune Warfarin Dosage 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 3Health News:Genetics May Help Fine-Tune Warfarin Dosage 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: